B
INZY

Bailard’s Inozyme Pharma INZY Stock Holding History

Bailard’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24,300
Closed -$127K – 780
2024
Q3 		$127K Hold
24,300
– – ﹤0.01% 722
2024
Q2 		$108K Hold
24,300
– – ﹤0.01% 712
2024
Q1 		$186K Buy
+24,300
New +$133K 0.01% 701

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bailard's INZY Position: Q4 2024 in Review

Bailard sold out of Inozyme Pharma (INZY) in Q4 2024, closing a stake of 24,300 shares — an estimated $127K sold.

Bailard first reported a position in INZY in Q1 2024 and held it in 3 quarters. The position peaked at $186K in Q1 2024. 105 funds tracked by Wall St. Rank hold INZY as of Q4 2024.

  • Bailard reported no remaining Inozyme Pharma position as of Q4 2024 after selling out during the quarter.
  • Bailard sold 24,300 Inozyme Pharma shares in Q4 2024, an estimated $127K.
  • Bailard first reported a position in Inozyme Pharma in Q1 2024 and held it in 3 quarters.
  • Bailard's Inozyme Pharma position peaked at $186K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2024.

Based on Bailard's 13F filing for Q4 2024, filed 5 Feb 2025.